NASDAQ:KPTI Karyopharm Therapeutics - KPTI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.89 +0.37 (+10.51%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.48▼$3.9150-Day Range$2.95▼$3.9252-Week Range$2.45▼$8.63Volume2.03 million shsAverage Volume2.66 million shsMarket Capitalization$440.89 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Karyopharm Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside144.2% Upside$9.50 Price TargetShort InterestHealthy14.76% of Shares Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment1.19Based on 2 Articles This WeekInsider TradingSelling Shares$229,983 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.30) to ($1.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.57 out of 5 starsMedical Sector92nd out of 1,004 stocksPharmaceutical Preparations Industry33rd out of 489 stocks 3.4 Analyst's Opinion Consensus RatingKaryopharm Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.50, Karyopharm Therapeutics has a forecasted upside of 144.2% from its current price of $3.89.Amount of Analyst CoverageKaryopharm Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted14.76% of the outstanding shares of Karyopharm Therapeutics have been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Karyopharm Therapeutics has recently decreased by 8.73%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKaryopharm Therapeutics has received a 71.09% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Other cancer medication", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Karyopharm Therapeutics is -1.11. Previous Next 3.4 News and Social Media Coverage News SentimentKaryopharm Therapeutics has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Karyopharm Therapeutics this week, compared to 2 articles on an average week.Search Interest44 people have searched for KPTI on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.MarketBeat Follows4 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $229,983.00 in company stock.Percentage Held by Insiders10.24% of the stock of Karyopharm Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.13% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($1.30) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -1.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Karyopharm Therapeutics (NASDAQ:KPTI) StockKaryopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.Read More Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KPTI Stock News HeadlinesMarch 23, 2023 | americanbankingnews.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $9.50 Consensus PT from BrokeragesMarch 21, 2023 | seekingalpha.comKaryopharm Therapeutics: Expanding Beyond The Crowded Multiple Myeloma MarketApril 1, 2023 | The Oxford Club (Ad)JP Morgan analyst: Oil to hit $380 per barrelJP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing. But there is one investment set to outperform all the rest.March 14, 2023 | finance.yahoo.comKaryopharm Announces Updated Selinexor Data in Patients with Treatment-Naïve Myelofibrosis to be Presented at AACR 2023March 8, 2023 | finance.yahoo.comKaryopharm to Participate at Barclays Global Healthcare ConferenceMarch 5, 2023 | finance.yahoo.comKaryopharm Therapeutics (NASDAQ:KPTI) shareholders have endured a 87% loss from investing in the stock three years agoFebruary 22, 2023 | msn.comThe Latest Analyst Ratings for Karyopharm TherapeuticsFebruary 21, 2023 | finance.yahoo.comKaryopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior TherapyApril 1, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. February 16, 2023 | benzinga.comKaryopharm Therapeutics Stock (NASDAQ:KPTI), Analyst Ratings, Price Targets, PredictionsFebruary 16, 2023 | finance.yahoo.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2022 Earnings Call TranscriptFebruary 16, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Prophase Labs (PRPH), Seagen (SGEN)February 14, 2023 | msn.comEarnings Preview For Karyopharm TherapeuticsFebruary 9, 2023 | finance.yahoo.comKaryopharm to Present at SVB Securities Global Biopharma ConferenceFebruary 8, 2023 | finance.yahoo.comKaryopharm to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023February 2, 2023 | benzinga.comKaryopharm Therapeutics Stock (NASDAQ:KPTI), Quotes and News SummaryJanuary 19, 2023 | benzinga.comBronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Karyopharm Therapeutics Inc. (KPTI) InvestigationJanuary 19, 2023 | msn.comKaryopharm gains as Piper issues bullish remarks citing cancer drugJanuary 15, 2023 | seekingalpha.comKaryopharm Therapeutics (KPTI) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- SlideshowJanuary 9, 2023 | finance.yahoo.comKaryopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue and Outlines 2023 ObjectivesJanuary 4, 2023 | finance.yahoo.comKaryopharm to Present at 41st Annual J.P. Morgan Healthcare ConferenceDecember 28, 2022 | seekingalpha.comKaryopharm: Recent Sell-Off Hits A New Buy TargetDecember 25, 2022 | seekingalpha.comKaryopharm: 6 Months Later, No Change In My StanceDecember 12, 2022 | markets.businessinsider.comKaryopharm Announces Updated Phase 1 Data Of Selinexor Combination In Treatment-Naïve MyelofibrosisDecember 12, 2022 | finance.yahoo.comKaryopharm Announces Presentation of Updated Phase 1 Selinexor Data in Patients with Treatment-Naïve Myelofibrosis at ASH 2022December 5, 2022 | finance.yahoo.comKaryopharm Announces $165 Million Private PlacementDecember 5, 2022 | finance.yahoo.comKaryopharm Announces Investor and Analyst Event at ASH 2022 on Selinexor Data in Patients with Treatment-Naïve MyelofibrosisSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KPTI Company Calendar Last Earnings2/15/2023Today4/01/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KPTI CUSIPN/A CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees442Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.50 High Stock Price Forecast$16.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+144.2%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-165,290,000.00 Net Margins-105.23% Pretax Margin-105.00% Return on EquityN/A Return on Assets-58.00% Debt Debt-to-Equity RatioN/A Current Ratio5.31 Quick Ratio5.25 Sales & Book Value Annual Sales$157.07 million Price / Sales2.81 Cash FlowN/A Price / Cash FlowN/A Book Value($0.15) per share Price / Book-25.93Miscellaneous Outstanding Shares113,340,000Free Float101,736,000Market Cap$440.89 million OptionableOptionable Beta0.04 Key ExecutivesRichard A. PaulsonPresident, CEO & Non-Executive DirectorSharon ShachamScientific Advisory BoardMike MasonChief Financial Officer, Treasurer & EVPReshma RangwalaChief Medical OfficerJames AccumannoChief Compliance OfficerKey CompetitorsErascaNASDAQ:ERASEdgewise TherapeuticsNASDAQ:EWTXLexicon PharmaceuticalsNASDAQ:LXRXMacroGenicsNASDAQ:MGNXTerns PharmaceuticalsNASDAQ:TERNView All CompetitorsInsiders & InstitutionsMetLife Investment Management LLCSold 12,015 shares on 3/23/2023Ownership: 0.026%Richard A PaulsonSold 3,506 sharesTotal: $11,078.96 ($3.16/share)Richard A PaulsonSold 33,033 sharesTotal: $100,089.99 ($3.03/share)Michael MasonSold 11,205 sharesTotal: $33,951.15 ($3.03/share)Sohanya Roshan ChengSold 11,239 sharesTotal: $34,054.17 ($3.03/share)View All Insider TransactionsView All Institutional Transactions KPTI Stock - Frequently Asked Questions Should I buy or sell Karyopharm Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KPTI shares. View KPTI analyst ratings or view top-rated stocks. What is Karyopharm Therapeutics' stock price forecast for 2023? 7 Wall Street research analysts have issued 1 year price targets for Karyopharm Therapeutics' stock. Their KPTI share price forecasts range from $5.00 to $16.00. On average, they predict the company's stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 144.2% from the stock's current price. View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts. How have KPTI shares performed in 2023? Karyopharm Therapeutics' stock was trading at $3.40 on January 1st, 2023. Since then, KPTI stock has increased by 14.4% and is now trading at $3.89. View the best growth stocks for 2023 here. Are investors shorting Karyopharm Therapeutics? Karyopharm Therapeutics saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 16,730,000 shares, a drop of 8.7% from the February 28th total of 18,330,000 shares. Based on an average daily trading volume, of 2,760,000 shares, the short-interest ratio is presently 6.1 days. View Karyopharm Therapeutics' Short Interest. When is Karyopharm Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our KPTI earnings forecast. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its earnings results on Wednesday, February, 15th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.09. The company had revenue of $33.58 million for the quarter, compared to the consensus estimate of $33.88 million. What ETFs hold Karyopharm Therapeutics' stock? ETFs with the largest weight of Karyopharm Therapeutics (NASDAQ:KPTI) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Future Gen 200 ETF (QQQS) and iShares Biotechnology ETF (IBB). What guidance has Karyopharm Therapeutics issued on next quarter's earnings? Karyopharm Therapeutics updated its FY 2023 earnings guidance on Wednesday, February, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $160.00 million-$175.00 million, compared to the consensus revenue estimate of $163.24 million. What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO? 31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY). What is Karyopharm Therapeutics' stock symbol? Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI." How do I buy shares of Karyopharm Therapeutics? Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Karyopharm Therapeutics' stock price today? One share of KPTI stock can currently be purchased for approximately $3.89. How much money does Karyopharm Therapeutics make? Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $440.89 million and generates $157.07 million in revenue each year. The company earns $-165,290,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. How many employees does Karyopharm Therapeutics have? The company employs 442 workers across the globe. How can I contact Karyopharm Therapeutics? Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for the company is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at ikarp@karyopharm.com. This page (NASDAQ:KPTI) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.